Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control ...
The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo ...
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
No­vo Nordisk said Thurs­day that it plans to even­tu­al­ly halt all of its hu­man in­sulin pen pro­duc­tion glob­al­ly, ...
Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese ...
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...
Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.
Zai Lab announces $200M share offering amid 47% revenue growth and plans for KarXT submission in China. Multiple companies report changes: Kronos Bio seeks alternatives, Allogene halts trial ...
The FDA has cleared PTC Ther­a­peu­tics’ gene ther­a­py for AADC de­fi­cien­cy, an ul­tra-rare dis­ease that im­pacts the ...